Review

miR-149 in Human Cancer: A Systemic Review

Yunjie He1*, Dandan Yu2*, Lingping Zhu1*, Shanliang Zhong2, Jianhua Zhao2, Jinhai Tang1, 3

1. The First Clinical School of Nanjing Medical University, Nanjing 210029, P.R. China;
2. Center of Clinical Laboratory, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing 210009, P.R. China;
3. Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, P.R. China.

* Equal contributors

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2017.05.16; Accepted: 2017.11.21; Published: 2018.01.01

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs that regulate post-transcriptional gene expression via binding to the 3′-untranslated region (3′-UTR) of targeted mRNAs. They are reported to play important roles in tumorigenesis and progression of various cancers. Among them, miR-149 was confirmed to be aberrantly regulated in various tumors. In this review, we provide a complex overview of miR-149, particularly summarize the critical roles of it in cancers and expect to lay the foundation for future works on this important microRNA.

Key words: miRNA, miR-149, cancer.

Introduction

MicroRNAs (miRNAs), a class of highly conserved noncoding RNA (ncRNA) molecules of approximately 22-nucleotide long, are post-transcriptional regulators that bind specifically to the 3′-untranslated region (3′-UTR) of targeted mRNAs, resulting in translational inhibition. In the last decade, miRNAs have emerged in many aspects of tumorigenesis, tumor development, metastasis, and drug resistance. Among them, miR-149, which can serve as an oncogene (oncomiR) and tumor suppressor, was found to be significantly dysregulated in various cancers, such as head and neck, lung, gastric, breast, prostate cancers and renal cell carcinoma (RCC) (Table 1, 2). In this review, to understand the overview of miR-149 better, we focused on enumerating and summarizing the specific functions and mechanisms of miR-149 in a wide range of cancers.

Structure and chromosomal localization of miR-149

Human miR-149 (hsa-mir-149; MIR149) is located at 2q37.3, encoded by only 1 exon and found to have polymorphisms. The predicted stem-loop structure of miR-149 determined using the RNA structure software is shown in (Figure 1A). The miR-149 hairpin gives rise to the “guide strand” miR-149-5p and the sister "passenger" strand miR-149-3p as shown in (Figure 1B). miR-149-5p is far more prevalent than miR-149-3p according to reads of deep sequencing. And the sequences of miR-149-5p and miR-149-3p are totally dissimilar, indicating inconsistent roles of them involved in human biological behavior.

Technical aspect of miR-149 extraction, detection and confirmation

The researchers initially examined 9 different mouse tissues using tissue-specific cloning and identified 34 novel miRNAs including miR-149, which found expressed higher in mouse heart by northern-blot. Then human miR-149 were identified through combined bioinformatics and sequence-directed cloning methods. Over 250 small RNA libraries were sequenced from 26 different organ systems and cell types of human and rodents.
Detailed and accurate information about mature sequences, precursors, genome location and conservation patterns of miR-149 were provided by this broad research. Moreover, Stephen S.C Chim et al. first detected miR-149 in human blood and confirmed that miR-149 was abundant in maternal plasma during pregnancy.[5]

Table 1. Targeted genes and dysregulation of miR-149-5p in various cancers.

| Hsa-miR-149-5p | Cancers          | Targeted gene |
|----------------|------------------|---------------|
| Upregulated    |                  |               |
| Acute myeloid leukemia | FASLG          |               |
| Prostate cancer  | SOX2, NANOG, Oct4 |               |
| Glioblastoma multiforme | Caspase-2     |               |
| Metastatic sporadic melanoma |            |               |
| Downregulated   |                  |               |
| Gastric cancer  | ZETB2            |               |
| Hepatocellular carcinoma | AKT1, PARP-2  |               |
| Glioblastoma multiforme | AKT1, Rap1b  |               |
| Renal cell carcinoma | PPM1F        |               |
| Lung cancer     | FOXM1            |               |
| Colorectal cancer | FOXM1, SPI, SRPX2, GPC1, EphB3 | |
| Breast cancer   | Rap1a, Rap1b, GIT1, NEDST1, EphB3 | |
| Gastric cancer  | IL-6             |               |
| Thyroid carcinoma | FO5L1          |               |
| Neuroblastoma   | Rap1             |               |
| Endometrial cancer |              |               |
| Laryngeal squamous cell carcinoma | | |
| Cervical carcinogenesis | | |
| Astrocytomas    |                  |               |

Table 2. Targeted genes and dysregulation of miR-149-5p in various cancers.

| Hsa-miR-149-3p | Cancers          | Targeted gene |
|----------------|------------------|---------------|
| Upregulated    |                  |               |
| Melanoma       | GSK3a            |               |
| T-cell acute lymphoblastic leukemia | JunB           |               |
| Glioma         |                  |               |
| Liver cancer   |                  |               |
| Downregulated  |                  |               |
| Neuroblastoma  | AKT1, E2F1       |               |
| Gastric cancer  | Wnt-1            |               |
| Pancreatic cancer | AKT1           |               |

The potential interactions of miR-149 with other molecules

The targeted genes and pathways potentially affected by miR-149-5p and miR-149-3p identified using the Diana-MicroT and TagetScan tools are shown in (Figure 1C, D). Undoubtedly, the gene and pathway signatures of miR-149-5p and miR-149-3p are totally different. B4GAL T1, ST3GAL2, B3GNT7, CHST2, B4GAL T2, SLC18A1, MAG, SYK, VEGFA, PIK3R6, AKT1, RHOC, TNS1 and so on were found as the targeted genes of miR-149-5p. AP1B1, GNPTAB, MFSD8, CTNS, CLN5, TPP1, CD68, IL-6, CCR9, CCR4, PDGF, NCKAP1L and so forth were predicted as the targeted genes of miR-149-3p.

The potential mechanisms of miR-149’s functions

The two isoforms of miR-149 are both predicted to target oncogene and tumor suppressor, leading to dual impacts among cancers. miR-149-5p participates mostly in ERBB-pathway, insulin signaling pathway, MAPK signaling pathway and chemokine signaling pathway, which are necessary for tumor growth, while miR-149-3p plays roles in toll-like receptor signaling pathway, T and B cell receptor signaling pathway, focal adhesion-pathway, vascular smooth muscle contraction-pathway and lysosome-pathway which also related closely to tumorigenesis and tumor progression. In the following sections, we will focus on discussing central roles of miR-149 related to biological functions of tumor, which were confirmed in various experiments and clinical samples.

miR-149 in cancer proliferation and apoptosis

Accelerated proliferation and decreased apoptosis of cancer cells contribute to the progress of tumor development. Tian P et al. described that miR-149-5p suppressed the apoptosis of the acute myeloid leukemia cell line THP-1 by targeting Fas ligand (FASLG), which in turn negatively affected the phosphorylated form of Fas-associated via death domain (p-FADD) and activation of caspases-2, 3, and 8.[6] Tomomi Fuji et al demonstrated that decreased miR-149-5p expression level was related to syndecan-1 (CD138, SDC-1), one of the four mammalian heparin sulfate proteoglycans silenced in prostate cancer.[7] The increased expression of syndecan-1 contributes to cell survival via regulating NOX-mediated reactive oxygen species (ROS) generation in androgen-independent prostate cancer cells.[8] The mRNA levels of the stem cell-related factors, SOX2, NANOG, and Oct4, increased significantly with decrease in miR-149-5p expression. Cell proliferation assay also showed that miR-149-5p promoted cell proliferation by suppressing these factors via p21 reduction. However, in human gastric cancer (GC), miR-149-5p inhibits proliferation and cell cycle progression via targeting ZBTB2, a repressor of the ARF-MDM2-p53-p21 pathway.[9, 10] ZBTB2 has been identified to either repress the transcription of tumor suppressors ARF, p53, and p21, or induce the expression of MDM2 proto-oncogene. Yanqiong Zhang et al investigated the tumor suppressive role of miR-149-5p via targeting AKT1 in human hepatocellular carcinoma (HCC).[11] In addition, they
identified AKT1 as an unfavorable factor in patients with HCC. miR-149-5p was found to regulate AKT1 expression by integrating bioinformatics and network analysis. The increased expression of miR-149-5p significantly inhibited HCC cell proliferation by regulating AKT1/mTOR pathway. And miR-149-5p inhibited human thyroid carcinoma WRO cells proliferation by targeting FOSL1 according to the study of Hiroki Takeshita et al. In human glioblastoma multiforme (GBM), miR-149-5p was also proved to act as a suppressor of AKT1 expression and inhibit the proliferative activities of U251 cell line, which has a mutation in codon 273 of the p53 gene. Interestingly, Xiaokun Shen et al showed that the stable overexpression of miR-149-5p leads to the promotion of cell viability of U87MG, a wild-type p53 cell line, inhibition of apoptosis, and induction of tumor xenograft growth in vivo. miR-149-5p targets caspase-2 via inactivation of the p53 and p21 pathways. In addition, miR-149-5p may exert opposite biological effects in p53 wild-type and p53 mutants; however, the specific underlying mechanisms remain to be investigated. Furthermore, on the basis of the study of Xu Y et al, miR-149-5p was markedly deregulated in neuroblastoma cell lines and primary tumor tissues associated with poor clinical outcome. In vitro, it was found that miR-149-5p downregulation promoted proliferation of neuroblastoma cells via targeting the small GTPases: Rap1.

Similar to miR-149-5p, miR-149-3p plays dual roles in cancer. Unlike other cancers, in human melanoma, wild-type p53 is often expressed at high levels. Lei Jin et al detected upregulated miR-149-3p expression in melanoma cell lines in response to endoplasmic reticulum (ER) stress. Next, they demonstrated that under ER stress, p53 binding to the p53-binding region at the GPC1 gene transcriptionally upregulates miR-149-3p expression. Furthermore, miR-149-3p targets the 3′UTR of GSK3β, which is known to target Mcl-1, consequently leading to apoptosis resistance in melanoma cells. miR-149-3p overexpression was observed in fresh human metastatic melanoma isolates. miR-149-3p-mediated pathway provided a reasonable explanation for the ineffectiveness of wild-type p53 in suppressing melanoma. miR-149-3p was also shown to serve as an oncogenic regulator by promoting proliferation and reducing apoptosis in T-cell acute lymphoblastic leukemia (T-ALL) cells via targeting JUNB, and subsequently downregulating p21 as well as upregulating cyclin D1, 4EBP1, and p70S6K. However, miR-149-3p was found to suppress the expression of polo-like kinase 1 (PLK1), a critical regulator of cell cycle progression and apoptosis, by targeting the 3′UTR of its mRNA, leading to tumor cell clonogenicity decrease and apoptosis induction. In addition, in human miR-149-3p-transfected neuroblastoma and HeLa cell lines, caspase3,7 activity was induced and cell growth was inhibited significantly. AKT1 and E2F1 were proven to be the direct targets of miR-149-3p. Importantly, an inverse correlation of miR-149-3p with E2F1 expression (P=0.026) was revealed in primary neuroblastoma samples. Furthermore, miR-149-3p was found upregulated in U87-MG cells following treatment of quinidine, a voltage-gated K+ channel blocker, leading to proliferation inhibition and apoptosis induction of glioma cells.

miR-149 in cancer migration and invasion

Cancer metastasis accounts for almost all cancer-related deaths. Metastasis is a multistep process, involving tumor cell dissemination from the primary tumor and colonizing distant organs. The improved ability of tumor cells to undergo migration and invasion contributes to the first step of this process. miR-149-5p was significantly downregulated in RCC tissues. The overexpression of miR-149-5p contributed to the suppression of cancer cell proliferation and migration. Forkhead box transcription factor (FOXM1) is a typical transcription factor and defined as having a common DNA-binding domain called Forkhead or winged-helix domain. FOXM1 regulates both G1-S and G2-M phases of cell cycle and mitotic spindle integrity, and its overexpression leads to tumor angiogenesis and metastasis. And in colorectal cancer, miR-149-5p suppresses cell migration and invasion by targeting FOXM1. miR-149-3p was also shown to function as a tumor suppressor via impairing cell spreading, migration, and invasion of basal-like breast cancer cells via targeting the small GTPases: Rap1a, Rap1b and downstream of integrin receptors. Cell metastasis depends on the activation of Rac, which is known to drive mesenchymal type of cancer cell motility. miR-149-5p has been proven to reduce Rac activation indirectly by Rap1a/b co-depletion. They also verified...
miR-149-5p was able to block the growth factor heregulin (HRG) and PI3K-Akt passway via targeting ErbB3, whose deregulated expression contributes to the transformed phenotype of breast cancer cells.[33] Moreover, cancer cells transfected with miR-149-5p blocked lung colonization in vivo. miR-149-5p targets G-protein-coupled receptor kinase-interacting protein (GIT1), another member of integrin signaling.[34] It has been known that GIT1 plays a central role in regulating fibronectin-induced focal adhesion formation and cell migration.[35, 36] Overexpression of miR-149-5p reduced the phosphorylation of focal adhesion kinase and paxillin, but enhanced the degradation of paxillin and α5β1 integrin. GIT1 depletion reduced α5β1-integrin-mediated cell adhesion to fibronectin. High GIT1 level and low miR-149-5p level were significantly associated with the advanced stages of breast cancer, especially lymph node metastasis.

miR-149 in drug sensitivity and resistance

Cancer resistance to chemotherapy, molecularly targeted therapies, and other anti-cancer drugs limits treatment effectiveness.[37] Studies have shown that miR-149 participates in regulating drug sensitivity and cancer resistance. In GBM, miR-149-5p was downregulated, while the chemosensitivity of glioblastoma cells to temozolomide (TMZ) was enhanced via targeting Rap1b.[38] Recent years, studies have shown that one type of dietary restrictions (DR): short time starvation (STS) is able to make chemotherapy more suitable.[39] Higher expression level of miR-149-5p in breast cancer cells: MDA-MB-231 and normal mammary epithelial cells: MCF10A treated with doxorubicin under STS for 48h could explain that miR-149-5p was involved in pathways related to increase drug sensitivity.[40] In adriamycin (ADM)-resistant human breast cancer cells, He DX et al demonstrated that the downregulation of miR-149-5p was attributed to hypermethylation of its 5’-UTR.[41] Chemoresistance was suppressed by miR-149-5p through targeting GlcNAc N-deacetylase/N-sulfotransferase-1 (NDST1). NDST1 has the ability to activate a heparin sulfate-related pathway involving heparanase, which contributes to chemoresistance. miR-149-5p not only decreases cell migration and invasion, but also increases the sensitivity of colorectal cancer cells to 5-Fluorouracil (5-FU) via targeting FOXM1.[42] In 5-FU-responding colorectal cancer tissues, the expression of miR-149-5p was significantly higher than that in non-responding tissues and inversely correlated with the mRNA level of FOXM1. It has been found that high level of bisphenol A (BPA) is one of risk factors to induce endometrial cancer (EC). The expression of miR-149-5p was reduced after BPA exposure, then leads to down-regulate DNA repair gene ADP-ribosylation factor 6 (ARF6) and tumor protein p53 (TP53).[43] These finding revealed a potential epigenetic mechanism among the risk of endometrial carcinogenesis. However, miR-149-5p was found upregulated in gefitinib-resistant human lung adenocarcinoma cell line and involved in the acquired gefitinib resistance.[44]

The study by Donghui Cao et al. revealed that 18β-glycyrrhetinic acid (GRA) could attenuate the severity of gastritis, suppress gastric tumorigenesis in transgenic mice, ameliorate the inflammatory microenvironment through the inhibition of COX-2 expression, and upregulate the expression of miR-149-3p which targeted Wnt-1.[45] In addition, dioscin, a natural product, is an active ingredient in some medicinal plants and has shown anti-tumor effects against many cancers.[46] In pancreatic cancer, dioscin was found to induce apoptosis and suppress the tumor growth of ASPC-1 and Panc-1 cell xenografts by upregulating miR-149-3p expression which targeted AKT1, increasing the expression levels of Bax, Apaf-1, cleaved caspase-3/9, and cleaved PARP, and suppressing Bcl-2 levels, which results in cytochrome c release.[47] Bafilomycin A1 is an inhibitor of the c subunit of the V-ATPase and has been investigated able to inhibit the proliferation and metastasis of cancer cells.[48] miR-149-3p was also found upregulated in BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines following bafilomycin A1 treatment.[49] However, on the basis of the study of Ma J et al, microcystin-LR (MC-LR) has been identified as one of risk factors for human primary hepatocellular cancer.[50, 51] Exposure of MC-LR was found promoted the expression of miR-149-3p, promoting miR-149-3p may be involved in MC-LR-hepatotoxicity, hepatitis and liver carcinoma.[52]

miR-149 in tumor microenvironment

Tumor microenvironment is now recognized as an important participant in metastatic progression and therapeutic responses.[53] Extracellular matrix (ECM) and numerous stromal cells, including blood endothelial cells, lymphatic endothelial cells, cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), mesenchymal stem cells (MSCs), immune cells, leukocytes, and adipocytes, constitute the tumor microenvironment.[54, 55]
B

>hsa-miR-149-5p MIMAT0000450
UCUGGCUCGUGUCUUCACUCCC

>hsa-miR-149-3p MIMAT0004609
AGGGAGGGACGGGGGCUGUGC
Figure 1. Structure, targeted genes and pathways of miR-149. (A): The predicted stem-loop structure of miR-149 determined using the RNA structure software. (B): The sequence of miR-149. (C, D): The targeted genes and pathways potentially affected by miR-149-5p and miR-149-3p identified using the Diana-MicroT and TargetScan tools.
Among the stromal cells, heterogeneous populations of CAFs are key players in multicellular stromal-dependent alterations that contribute to malignant initiation and progression. In addition, crosstalk between CAFs and tumor cells lead to tumor progression. CAFs are usually considered to be derived from normal fibroblasts (NFs), and they communicate with tumor cells via growth and inflammation factors. Inflammatory signaling pathways are considered highly promising targets to block the crosstalk between tumor cells and CAFs. Pu Li et al demonstrated that miR-149-5p links PGE2 and IL-6 signaling in mediating the communication between tumor cells and CAFs in GC. They showed that miR-149-5p regulated fibroblast activation protein (FAP) expression via targeting IL-6, and its expression was downregulated in GC CAFs. miR-149-5p was found to inhibit fibroblast activation by reducing IL-6 expression. In addition, CAFs enhanced epithelial-to-mesenchymal transition and the stem-like properties of GC cells in a miR-149-IL-6-dependent manner. Besides IL-6, PGE2 receptor 2 (PTGER2/EP2) was revealed as another target of miR-149-5p. *H. pylori* infection, a leading cause of human GC, caused the hypermethylation of miR-149-5p and induced COX-2/PGE2 as well as IL-6 signaling pathways.

Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes, especially in the endothelial cells. Glypicans (GPCs) are frequently overexpressed in many cancers and recognized to play a role in tumorigenesis and angiogenesis. GPC1 promoted FGF2 binding to its receptor (FGFR1), subsequently enhancing FGF2-FGFR1 activation and signaling. miR-149, including miR-149-5p and miR-149-3p, was found to be located within the first intron of GPC1 gene and showed targeting activity towards both GPC1 and FGFR1 in endothelial cells. Decreased FGF2 signaling in endothelial cells and reduced neovascularization were observed *in vivo* following miR-149 overexpression. Notably, FGF2 was found to stimulate the expression of miR-149, thereby assuring the steady state of FGF2-induced responses in endothelial cells.

**miR-149 as potential therapeutic targets**

As we discussed above, miR-149 plays important roles in tumorigenesis and tumor progression of various cancers. There also have been a large number of studies about exploring the effect using miR-149 as therapeutic targets. Chen Y et al observed a reduction in proliferation and increase in the apoptosis of prostate cancer stem cells from TSU cell line via the downregulated expression of miR-149-5p.
rs2292832 was verified associated with better over survival (OS), and might function through DNA topoisomerases 1 (TOP1) pathway in non-small cell lung cancer.\textsuperscript{85,86} And in colorectal cancer, miR-149-5p was found to be epigenetically silenced, which was associated with the hypermethylation of the neighboring CpG Island. miR-149-5p acts as a tumor suppressor via targeting a potential oncogenic protein, Specificity Protein 1 (SP1).\textsuperscript{87,88} Wilting SM et al also demonstrated methylation-mediated transcriptional repression of miR-149-5p participated in human papillomavirus (HPV) induced cervical carcinogenesis.\textsuperscript{89} Another study demonstrated that miR-149-5p was downregulated in colorectal cancer, and it regulated the expression of SRPX2.\textsuperscript{90} AKT1 was identified as an unfavorable prognostic factor for patients with HCC. Zhang Y et al found that miR-149 functions as a tumor suppressive miRNA via targeting AKT1 in patients with HCC by using five online programs for miRNA target prediction.\textsuperscript{91} Lin L et al studied the expression of miR-149-5p and PARP-2 in HCC tumor tissues, and their roles in sensitizing chemo/radiotherapy. The high expression level of PARP-2 and low expression level of miR-149-5p were found to be correlated with larger tumor mass, increased capsular and vascular invasion, and lymph node metastases. High PARP-2 and low miR-149-5p levels were identified as poor prognosis factors, and they reduced sensitivity to chemotherapy and radiotherapy in xenograft HCC animal models.\textsuperscript{92} Xue L et al aimed to investigate the prognostic value of miR-149-5p in glioma.\textsuperscript{93} They found that the expression of miR-149-5p was significantly lower in tumor tissues compared to that in normal tissues. Improved survival duration and lower mortality risk were also observed using Kaplan-Meier and multivariate analysis. Furthermore, it was revealed that AKT/mTOR signaling was hyperactive in low miR-149 expressing tissues. miR-149-5p was also proven to play critical roles in astrocytomas and laryngeal squamous cell carcinoma.\textsuperscript{94} miR-149-5p expression was significantly lower in tumor tissues than in normal brain and vocal cord polyp tissues. Shorter survival duration was seen in patients with lower miR-149-5p expression. However, in Yang C et al’s study, the expression of miR-149-5p was reported to be increased in NSCLC tissues using either small RNA-sequencing or qRT-PCR validation.\textsuperscript{95} miR-149-5p was also found overexpressed in castration-resistant prostate cancer. And in upper tract urothelial carcinoma, miR-149-5p was identified as independently associated with cancer-specific survival.\textsuperscript{96} Besides, overexpression of miR-149-3p was found in plasma of melanoma patients compared with healthy controls. miR-149-3p was identified as a biomarker with high diagnostic power in early stage of melanoma.\textsuperscript{97} And miR-149-3p overexpression was also investigated strongly correlated in uveal melanoma patients with liver metastasis.\textsuperscript{98}

Recently, serum or plasma exosomal miRNAs have emerged as novel markers for diagnosis and prognostic evaluation in patients with various cancers.\textsuperscript{99} Extracellular vesicles (EVs) and exosomes are membrane-derived vesicles that are actively secreted by cells. EVs with a diverse range of sizes (100–1,000 nm in diameter) contain microvesicles and exosomes, which originate by budding from the plasma membrane of cells. Exosomes, typically smaller than 150 nm in diameter, are generated inside multivesicular endosomes or multivesicular bodies (MVBs). When these compartments fuse with the plasma membrane, exosome secretion is activated.\textsuperscript{100} A previous study showed that EVs and exosomes contain numerous molecules, such as cell-specific proteins, lipids, miRNAs, and abundant miRNAs.\textsuperscript{101-103} Owing to the protective function of EVs or exosomes against degradation by RNAse enzymes, exosomal miRNAs are stable in blood or other body fluids, making them ideal candidates for biomarkers in cancers. Pfeffer SR et al. showed that exosomal miR-149-5p was expressed at significantly higher levels in patients with metastatic sporadic melanoma compared to that in familial melanoma patients or unaffected control subjects, suggesting that miR-149-5p could be a poor prognostic factor in melanoma.\textsuperscript{104} As we mentioned above, miR-149-5p was found to have targeting activity towards GPC1 in endothelial cells. Similarly, miR-149-5p decreased GPC1 expression in colorectal cancer cell lines. Moreover, miR-149-5p was significantly decreased in GPC+ exosomes from tumor tissues and plasma of colorectal cancer patients compared to that in peritumoural tissues and plasma of healthy controls.\textsuperscript{105}

**Conclusions**

miR-149-5p or miR-149-3p plays dual roles in the proliferation and apoptosis of various tumors (Figure 2). In cancer metastasis, miR-149-5p is found to be an important tumor suppressor, and its expression was downregulated (Figure 3). Currently, both miR-149-5p and miR-149-3p are confirmed to increase drug sensitivity according to most of the literature (Figure 4). In tumor microenvironment, miR-149-5p regulated FAP expression on CAFs via targeting IL-6, leading to fibroblast activation inhibition and its expression was downregulated in gastric cancer. Overexpression of miR-149-5p or miR-149-3p alleviated FGF2 signaling in endothelial cells and

http://www.jcancer.org
reduced neovascularization (Figure 5). miR-149-5p gene polymorphisms contribute to alter susceptibility to cancers. Therefore, it can be suggested that miR-149 could serve as biomarkers and therapeutic targets in numerous cancers.

Figure 2. Dual roles of miR-149-5p and miR-149-3p in proliferation and apoptosis. (A): miR-149-5p. (B): miR-149-3p.
Figure 3. miR-149-5p found to be an important tumor suppressor of metastasis.

Figure 4. miR-149-5p and miR-149-3p confirmed to increase drug sensitivity.
miR-149-3p and miR-149-5p participate in tumor microenvironment. (A) miR-149-5p mediates the crosstalk between tumor cells and CAFs: H. pylori infection leads to induce PGE2 signaling and result in reduction of miR-149-5p in CAFs and increase IL-6 secretion. (B) Overexpression of miR-149-5p or miR-149-3p alleviated FGF2 signaling in endothelial cells and reduced neovascularization via targeting GPC1 and FGFR1.

Figure 5. miR-149-3p and miR-149-5p participate in tumor microenvironment.

Acknowledgement

This research was supported by National Program on Key Research Project (No. 2016YFC0905900), Medical Training Programme Foundation for the Talents by Jiangsu Provincial Department of health (No.17 [2016]), The 333 Talent Project of Jiangsu Province, top-level (No.4 [2016]), the National key clinical specialist construction Programs of China (No.544 [2013]), Major Program of Natural Science Foundation of Jiangsu Province (No. BL2014090), Natural Science Foundation of Jiangsu Province (No. BK20151579), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231802). This study was also funded by the National Natural Science Foundation of China (grant number 81602551), the Key Research Program for the Social Development of Jiangsu Province, China (BE2015718) and the National Natural Science Foundation of China (No. 81602551).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature cell biology. 2009; 11: 228-34.
2. Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS letters. 2011; 585: 2087-99.
3. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Current biology: CB. 2002; 12: 735-9.
4. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007; 129: 1401-14.
5. Chinn SSC, Shing TKF, Hung ECW, Lau Tk, Chiu RWK, et al. Detection and Characterization of Placental MicroRNAs in Maternal Plasma. Clinical Chemistry. 2008; 54: 482-90.
6. Tian P, Yan L. Inhibition of MicroRNA-149-5p Induces Apoptosis of Acute Myeloid Leukemia Cell Line THP-1 by Targeting Fas Ligand (FASLG). Medical science monitor: international medical journal of experimental and clinical research. 2016; 22: 5116-23.
7. Fujii T, Shimada K, Tsutsumi Y, Fujimoto K, Konishi N. Syndecan-1 responsive microRNAs-126 and 149 regulate cell proliferation in prostate cancer. Biochem Biophys Res Commun. 2015; 456: 183-9.
8. Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouchi Y, Konishi N. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci. 2009; 100: 1248-54.
9. Wang Y, Zheng X, Zhang Z, Zhou J, Zhao G, Yang J, et al. MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB12 in human gastric cancer. PLoS One. 2012; 7: e41693.
10. Jeon BN, Choi WI, Yu MY, Yoon AR, Kim MH, Yun CO, et al. ZBTB12, a novel master regulator of the p53 pathway. The Journal of biological chemistry. 2009; 284: 17935-46.
11. Zhang Y, Guo X, Xiong L, Yu L, Li Z, Guo Q, et al. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway. Molecular cancer. 2014; 13: 253.
12. Takeshita H, Shiozaki A, Bai XH, Itakura K, Kim H, Yang BB, et al. XIAP, a new adaptor protein, regulates expression of tumor suppressive microRNAs in cancer cells. PLoS One. 2013; 8: e59057.
13. Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG, Sun BM. MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. International journal of immunopathology and pharmacology. 2012; 25: 871-81.
14. Shen X, Li J, Liao W, Wang J, Chen H, Yao Y, et al. microRNA-149 targets caspase-2 in glioma progression. Oncotarget. 2016; 7: 26388-99.
15. Xu Y, Chen X, Lin L, Chen H, Yu S, Li D. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification. Biochimie. 2017; 139: 1-8.
with gastrointestinal cancer risk. Molecular carcinogenesis. 2012; 51 Suppl 1: E21-31.

71. Pan XM, Xiao X, Qin HJ, Zhang Z, Li ZH, Gao LB, et al. MicroRNA variants and colorectal cancer risk: a meta-analysis. Genetics and molecular research: GMR. 2016; 15.

72. Liu XX, Wang M, Xu D, Yang JH, Kang HF, Wang XJ, et al. Quantitative Assessment of the Association between Genetic Variants in MicroRNAs and Colorectal Cancer Risk. BioMed research international. 2015; 2015: 276410.

73. Jia H, Yu H, Liu Q. Single nucleotide polymorphisms of MR-149 gene rs2292832 contributes to the risk of hepatocellular carcinoma, but not overall cancer: a meta-analysis. Minerva medica. 2016; 107: 259-69.

74. Wang XI, Wang FR, Tang YF, Zou HZ, Zhao YQ. Association of miR-149>C>T polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. Genetics and molecular research: GMR. 2014; 13: 5048-54.

75. Feng Y, Duan S, Song C, Zhao X, Dai L, Cui S. Systematic evaluation of cancer risk associated with rs229832 in miR149 and rs895819 in miR27a: a comprehensive and updated metaanalysis. Oncotarget. 2016; 7: 22368-84.

76. Liu MF, Chen WQ, He YZ, Gu YL. Role of miR-149>C>T polymorphisms on the risk of hepatocellular carcinoma in Chinese population. Genetics and molecular research: GMR. 2014; 13: 7184-9.

77. Sushma PS, Jamil K, Kumar PU, Satyanarayana U, Ramakrishna M, Triveni B. Genetic Variation in MicroRNAs and Risk of Oral Squamous Cell Carcinoma in South Indian Population. Asian Pac J Cancer Prev. 2015; 16: 7389-94.

78. Wei WJ, Li ZW, Li DS, Wang Y, Zhu YX, Wang ZY, et al. Association of the miR-149 Rs2292832 polymorphism with papillary thyroid cancer risk and clinicopathologic characteristics in a Chinese population. International journal of molecular sciences. 2014; 15: 20068-81.

79. Wu J, Lv S, An J, Lu C. Pre-miR-149 rs71428439 polymorphism is associated with increased cancer risk and AKT1/cyclinD1 signaling in hepatocellular carcinoma. International journal of clinical and experimental medicine. 2015; 8: 13628-33.

80. Tu HF, Liu CJ, Chang CL, Wang PW, Kao SY, Yang CC, et al. The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma. PLoS One. 2012; 7: e51606.

81. Wang Z, Wei M, Ren Y, Liu H, Wang M, Shi K, et al. miR-149 rs7428439 polymorphism and risk of clear cell renal cell carcinoma: a case-control study. Tumour Biol. 2014; 35: 12127-30.

82. Li L, Liu T, Li Z, Zhang L, Zhang Z. The miR-149 rs2292832 T/C polymorphism may decrease digestive cancer susceptibility: an updated meta-analysis. International journal of clinical and experimental medicine. 2015; 8: 15351-61.

83. Wang C, Sturgis EM, Chen X, Zheng H, Wei Q, Li G. Pre-miRNA variants as predictors of clinical outcome in patients with squamous cell carcinomas of the nonoropharynx. Oncotarget. 2016; 7: 26444-53.

84. Huang GL, Lu Y, Pu XX, He YX, Chen ML, Li YZ, et al. Association study between miR-149 gene polymorphism and nasopharyngeal carcinoma. Biomedical reports. 2013; 1: 599-603.

85. Lingxi X, Zhuhua Y, Xuelian L, Yangwu R, Haibo Z, Yuxia Z, et al. Genetic variants in microRNAs predict non-small cell lung cancer prognosis in Chinese female population in a prospective cohort study. Oncotarget. 2016; 7: 83101-14.

86. Hong MJ, Choi YY, Jang JA, Jung HJ, Lee SY, Lee WK, et al. Association between genetic variants in pre-microRNAs and survival of early-stage NSCLC. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2013; 8: 703-10.

87. Wang F, Ma YL, Zhang P, Shen TY, Shi CQ, Yang YZ, et al. SPI mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol. 2013; 229: 12-24.

88. Safe S. MicroRNA-Specificity Protein (Sip) Transcription Factor Interactions and Significance in Carcinogenesis. Current pharmacology reports. 2015; 1: 73-88.

89. Wilting SM, Verlaat W, Jaspers A, Makazaija NA, Agami R, Meijer CJ, et al. Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics. 2013; 8: 220-8.

90. Oster B, Limet L, Christensen LL, Thorsen K, Ongen H, Dermitzakis ET, et al. Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer. International journal of cancer. 2013; 132: 2303-15.

91. Lin L, Zhang YD, Chen ZY, Chen Y, Ren CP. The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemoradiotherapy. Tumour Biol. 2016; 37: 12339-46.

92. Xu L, Wang Y, Yue S, Zhang J. Low MiR-149 expression is associated with unfavorable prognosis and enhanced Akt/mTOR signaling in glioma. International journal of clinical and experimental pathology. 2015; 8: 11178-84.

93. Xu Y, Lin YF, Yang D, Zhang G, Zhou HF. Clinical Significance of miR-149 in the Survival of Patients with Laryngeal Squamous Cell Carcinoma. BioMed research international. 2016; 2016: 8561251.

94. Li D, Chen P, Li YX, Zhang LY, Xiong W, Zhou M, et al. Grade-specific expression profiles of miRNAs/miRNAs and docking study in human grade I-III astrocytomas. Omics: a journal of integrative biology. 2011; 15: 673-82.

95. Yang C, Sun C, Liang X, Xie S, Huang J, Li D. Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer. Cancer gene therapy. 2016; 23: 90-7.